NCT01943006

Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis

Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment of Superficial Infusion Thrombophlebitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 144 (actual)
• Sponsor: Medinova AG · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Patients receiving nutritional emulsion for at least 3 days will be treated with Hirudoid cream or placebo cream to prevent and treat phlebitis caused by the infusion. The treatment is continued after the end of infusion for at least 7 days. Number of patients developing superficial phlebitis and duration of phlebitis will be recorded.

Conditions

• Thrombophlebitis
• Phlebitis

Interventions

Type	Name	Description
DRUG	Hirudoid cream 0.3 % Mucopolysaccharide polysulfate	Hirudoid cream
DRUG	Placebo cream without active substance

Timeline

• Start date: 2015-05-01
• Primary completion: 2017-02-01
• Completion: 2017-03-01
• First posted: 2013-09-16
• Last updated: 2017-12-14

Locations

4 sites across 1 country: Thailand